From a pathogenic standpoint however, a myeloid or lymphoid clonal origin can be detected in nearly half of HES (32, 33), and sensitivity to imatinib has been reported in a number of FIP1L1-PDGFRA (F/P)-negative HES patients bearing other novel fusion genes (34–36). The gene discussed is FIP1L1; the disease is hypereosinophilic syndrome.